A recent phase III study compared the oral selective estrogen receptor degrader giredestrant plus everolimus with standard of care in patients with estrogen receptor–positive, HER2-negative advanced breast cancer to assess progression-free and overall survival. Take this quiz to test your knowledge of the study results, which were presented at the ESMO Congress 2025.
